Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

Andrés Redondo,1,* Virginia Martínez,1,* Pilar Zamora,1 Beatriz Castelo,1 Alvaro Pinto,1 Patricia Cruz,1 Oliver Higuera,1 Marta Mendiola,2 David Hardisson,3 Enrique Espinosa11Medical Oncology Department, 2Translational Oncology and Molecular Pathology Laboratory, 3Pathology De...

Full description

Bibliographic Details
Main Authors: Redondo A, Martínez V, Zamora P, Castelo B, Pinto A, Cruz P, Higuera O, Mendiola M, Hardisson D, Espinosa E
Format: Article
Language:English
Published: Dove Medical Press 2014-11-01
Series:OncoTargets and Therapy
Online Access:http://www.dovepress.com/continuation-of-bevacizumab-and-addition-of-hormone-therapy-following--peer-reviewed-article-OTT

Internet

http://www.dovepress.com/continuation-of-bevacizumab-and-addition-of-hormone-therapy-following--peer-reviewed-article-OTT

Similar Items